Furthermore, obinutuzumab, often used in combination with venetoclax in CLL treatment, has been demonstrated to induce LMP in CLL cells, contributing to its cell death [23,24], but the mechanism of this cell death remains unclear. This evidence concerns the gene PDLIM7 and B-cell chronic lymphocytic leukemia.